1. Home /
  2. Biotechnology

Biotechnology

Amgen Climbs After Winning Patent Case on Enbrel

Amgen Climbs After Winning Patent Case on Enbrel

Amgen's patents for Enbrel likely to be protected until 2029.

Bluebird Bio Drops Following William Blair Downgrade

Bluebird Bio Drops Following William Blair Downgrade

William Blair is concerned about the company's transition from drug development to commercialization.

Checking In on 2 Small Biotech Names That Had Big Quarters

Checking In on 2 Small Biotech Names That Had Big Quarters

Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.

Amarin Dives on Surprise FDA Heart-Drug Review

Amarin Dives on Surprise FDA Heart-Drug Review

Shares of Amarin plunge after the biotech company's surprise revelation that the Food and Drug Administration will hold an advisory panel review of its heart drug Vascepa.

Investing in Small Biotechs? Check Out the CFO First

Investing in Small Biotechs? Check Out the CFO First

They're the most important executive at most small developmental or early commercialization concerns.

Cambrex Soars on Buyout Deal With Private-Equity Firm Permira

Cambrex Soars on Buyout Deal With Private-Equity Firm Permira

Shares of life-sciences company Cambrex surge after the company strikes a deal to be acquired by pharmaceutical-focused private-equity firm Permira funds for $2.4 billion, including debt.

Allakos Stock Doubles on Positive Stomach Disease Drug Study Data

Allakos Stock Doubles on Positive Stomach Disease Drug Study Data

Analyst at William Blair says Allakos is a leader in research for a treatment for a rare stomach disease.

GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails

GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails

The company announces that rivipansel, which was developed in partnership with Pfizer, didn't meet primary or secondary endpoints.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Amgen Changes the Narrative With Cancer Drug Breakthrough

Amgen Changes the Narrative With Cancer Drug Breakthrough

Amgen built on the momentum at a recent conference on its Q2 earnings call as management highlighted recent positive developments for its KRAS inhibitor drug.